| Phenotypic Profile |
| Category |
Entity |
Quantity |
Experimental Paradigm |
Age at Testing |
| Motor phenotype |
General locomotor activity: ambulatory activity1 |
Restored
Description: Isoguvacine treatment increased distance travelled to control levels.
Exp Paradigm: NA
|
Open field test |
6 weeks |
| |
|
Description: Isoguvacine treatment increased distance travelled to control levels.
Exp Paradigm: NA |
|
|
| Motor phenotype |
General locomotor activity1 |
No adverse effect
Description: Isoguvacine treatment did not change total number of arm entries.
Exp Paradigm: NA
|
Elevated plus maze test |
6 weeks |
| |
|
Description: Isoguvacine treatment did not change total number of arm entries.
Exp Paradigm: NA |
|
|
| Neuroanatomy / Ultrastructure / Cytoarchitecture |
Neuronal number: interneurons1 |
Restored
Description: Isoguvacine increased parvalbumin positive interneurons in the primary somatosensory cortex but not in the primary visual cortex.
Exp Paradigm: NA
|
Immunohistochemistry |
6 weeks |
| |
|
Description: Isoguvacine increased parvalbumin positive interneurons in the primary somatosensory cortex but not in the primary visual cortex.
Exp Paradigm: NA |
|
|
| Neuroanatomy / Ultrastructure / Cytoarchitecture |
Neuronal number: interneurons1 |
Refractory
Description: Isoguvacine treatment did not change number of parvalbumin positive interneurons in the basolateral amygdala.
Exp Paradigm: NA
|
Immunohistochemistry |
6 weeks |
| |
|
Description: Isoguvacine treatment did not change number of parvalbumin positive interneurons in the basolateral amygdala.
Exp Paradigm: NA |
|
|
| Neurophysiology |
Spontaneous post synaptic event amplitude: inhibitory currents1 |
No adverse effect
Description: Isoguvacine treatment did not change sipsc amplitude in the primary somatosensory cortex or the visual cortex.
Exp Paradigm: NA
|
Whole-cell patch clamp |
6 weeks |
| |
|
Description: Isoguvacine treatment did not change sipsc amplitude in the primary somatosensory cortex or the visual cortex.
Exp Paradigm: NA |
|
|
| Neurophysiology |
Synaptic transmission1 |
Restored
Description: Isoguvacine increased excitatory to inhibitory ratio in mutants.
Exp Paradigm: NA
|
Whole-cell patch clamp |
6 weeks |
| |
|
Description: Isoguvacine increased excitatory to inhibitory ratio in mutants.
Exp Paradigm: NA |
|
|
| Neurophysiology |
Spontaneous post synaptic event amplitude: excitatory currents1 |
No adverse effect
Description: Isoguvacine treatment did not change sepsc amplitude in the primary somatosensory cortex or the visual cortex.
Exp Paradigm: NA
|
Whole-cell patch clamp |
6 weeks |
| |
|
Description: Isoguvacine treatment did not change sepsc amplitude in the primary somatosensory cortex or the visual cortex.
Exp Paradigm: NA |
|
|
| Neurophysiology |
Spontaneous post synaptic event frequency: inhibitory currents1 |
Side effect
Description: Isoguvacine treatment increased sipsc frequency in the visual cortex but not the primary somatosensory cortex.
Exp Paradigm: NA
|
Whole-cell patch clamp |
6 weeks |
| |
|
Description: Isoguvacine treatment increased sipsc frequency in the visual cortex but not the primary somatosensory cortex.
Exp Paradigm: NA |
|
|
| Neurophysiology |
Spontaneous post synaptic event frequency: excitatory currents1 |
No adverse effect
Description: Isoguvacine treatment did not change sepsc frequency in the primary somatosensory cortex or the visual cortex.
Exp Paradigm: NA
|
Whole-cell patch clamp |
6 weeks |
| |
|
Description: Isoguvacine treatment did not change sepsc frequency in the primary somatosensory cortex or the visual cortex.
Exp Paradigm: NA |
|
|
| Neurophysiology |
Synaptic transmission1 |
Refractory
Description: Isoguvacine treatment did not change excitatory to inhibitory ratio in mutants.
Exp Paradigm: NA
|
Whole-cell patch clamp |
6 weeks |
| |
|
Description: Isoguvacine treatment did not change excitatory to inhibitory ratio in mutants.
Exp Paradigm: NA |
|
|
| Repetitive behavior |
Self grooming: perseveration1 |
No adverse effect
Description: Isoguvacine treatment did not change self-grooming.
Exp Paradigm: NA
|
Grooming behavior assessments |
6 weeks |
| |
|
Description: Isoguvacine treatment did not change self-grooming.
Exp Paradigm: NA |
|
|
| Repetitive behavior |
Repetitive digging1 |
Refractory
Description: Isoguvacine treatment did not change the number of marbles buried.
Exp Paradigm: NA
|
Marble-burying test |
6 weeks |
| |
|
Description: Isoguvacine treatment did not change the number of marbles buried.
Exp Paradigm: NA |
|
|
| Sensory |
Sensorimotor gating1 |
Refractory
Description: Isoguvacine treatment did not change percent prepulse inhibition of the startle response to a 125 db noise, when the startle noise is preceded by a prepulse at 80db.
Exp Paradigm: NA
|
Prepulse inhibition |
6 weeks |
| |
|
Description: Isoguvacine treatment did not change percent prepulse inhibition of the startle response to a 125 db noise, when the startle noise is preceded by a prepulse at 80db.
Exp Paradigm: NA |
|
|
| Sensory |
Startle response: acoustic stimulus1 |
No adverse effect
Description: Isoguvacine treatment did not change response to acoustic prepulse.
Exp Paradigm: NA
|
Acoustic startle reflex test |
6 weeks |
| |
|
Description: Isoguvacine treatment did not change response to acoustic prepulse.
Exp Paradigm: NA |
|
|
| Sensory |
Sensorimotor gating: tactile cue1 |
Restored
Description: Isoguvacine decreased the increase of tactile prepulse inhibition of an acoustic startle response assay in mutants.
Exp Paradigm: NA
|
Prepulse inhibition |
6 weeks |
| |
|
Description: Isoguvacine decreased the increase of tactile prepulse inhibition of an acoustic startle response assay in mutants.
Exp Paradigm: NA |
|
|
| Sensory |
Tactile memory1 |
Refractory
Description: Isoguvacine treatment did not change preference for object with novel texture.
Exp Paradigm: NA
|
Textured novel object recognition test (t-nort) |
6 weeks |
| |
|
Description: Isoguvacine treatment did not change preference for object with novel texture.
Exp Paradigm: NA |
|
|
| Sensory |
Sensorimotor gating: tactile cue1 |
Restored
Description: Isoguvacine decreased response to air puff alone in mutants.
Exp Paradigm: NA
|
Response to air puff |
6 weeks |
| |
|
Description: Isoguvacine decreased response to air puff alone in mutants.
Exp Paradigm: NA |
|
|
| Sensory |
Startle response: acoustic stimulus1 |
Refractory
Description: Isoguvacine treatment did not change startle response to 125db startle noise in mutants.
Exp Paradigm: NA
|
Acoustic startle reflex test |
6 weeks |
| |
|
Description: Isoguvacine treatment did not change startle response to 125db startle noise in mutants.
Exp Paradigm: NA |
|
|
| Social behavior |
Social memory1 |
Restored
Description: Isoguvacine increased preference for novel mouse over familiar mouse in mutants.
Exp Paradigm: NA
|
Three-chamber social approach test |
6 weeks |
| |
|
Description: Isoguvacine increased preference for novel mouse over familiar mouse in mutants.
Exp Paradigm: NA |
|
|
| Social behavior |
Social approach1 |
Restored
Description: Isoguvacine increased preference for novel mouse over novel object in mutants.
Exp Paradigm: NA
|
Three-chamber social approach test |
6 weeks |
| |
|
Description: Isoguvacine increased preference for novel mouse over novel object in mutants.
Exp Paradigm: NA |
|
|
| Developmental profile |
Size/growth1 |
Restored
Description: Isoguvacine treatment increased body weight in mutants.
Exp Paradigm: NA
|
Body weight measurement |
NA |
| |
|
Description: Isoguvacine treatment increased body weight in mutants.
Exp Paradigm: NA |
|
|
| Developmental profile |
General characteristics1 |
Restored
Description: Mutants show clean shiny coat, clear eyes and normal stance
Exp Paradigm: A score of 0 indicated a clean shiny coat, clear eyes and normal stance. a score of 1 indicated the appearance of dull eyes, dull/ungroomed coat and somewhat hunched stance. a score of 2 denoted narrowed or crusted eyes, piloerection and a hunched posture. a score of 3 indicated severe eye narrowing, profound piloerection or loss of fur, and severely hunched posture.
|
Macroscopic analysis |
3 weeks |
| |
|
Description: Mutants show clean shiny coat, clear eyes and normal stance
Exp Paradigm: A score of 0 indicated a clean shiny coat, clear eyes and normal stance. a score of 1 indicated the appearance of dull eyes, dull/ungroomed coat and somewhat hunched stance. a score of 2 denoted narrowed or crusted eyes, piloerection and a hunched posture. a score of 3 indicated severe eye narrowing, profound piloerection or loss of fur, and severely hunched posture. |
|
|
| Emotion |
Habituation to aversive stimuli1 |
Restored
Description: Isoguvacine treatment increased the decrease in startle amplitude.
Exp Paradigm: NA
|
Prepulse inhibition |
6 weeks |
| |
|
Description: Isoguvacine treatment increased the decrease in startle amplitude.
Exp Paradigm: NA |
|
|
| Emotion |
Exploratory activity1 |
Restored
Description: Isoguvacine treatment decreased time spent investigating objects to control levels.
Exp Paradigm: NA
|
Novel object recognition test |
6 weeks |
| |
|
Description: Isoguvacine treatment decreased time spent investigating objects to control levels.
Exp Paradigm: NA |
|
|
| Emotion |
Anxiety1 |
Restored
Description: Isoguvacine decreased time in the center in mutants.
Exp Paradigm: NA
|
Open field test |
6 weeks |
| |
|
Description: Isoguvacine decreased time in the center in mutants.
Exp Paradigm: NA |
|
|
| Emotion |
Anxiety1 |
Restored
Description: Isoguvacine decreased time in open arms in mutants.
Exp Paradigm: NA
|
Elevated plus maze test |
6 weeks |
| |
|
Description: Isoguvacine decreased time in open arms in mutants.
Exp Paradigm: NA |
|
|
| Learning & memory |
Object recognition memory: long-term recall1 |
Refractory
Description: Isoguvacine treatment did not change preference for object with novel shape after 5 min or 1 hour retention.
Exp Paradigm: NA
|
Novel object recognition test |
6 weeks |
| |
|
Description: Isoguvacine treatment did not change preference for object with novel shape after 5 min or 1 hour retention.
Exp Paradigm: NA |
|
|
|
| Not Reported: |
Circadian sleep/wake cycle, Communications, Immune response, Maternal behavior, Molecular profile, Physiological parameters, Seizure, |
